Objective-In a phase III clinical trial (PLATelet inhibition and patient Outcomes, PLATO), ticagrelor provided better clinical outcomes than clopidogrel in patients with acute coronary syndromes. In addition to P2Y 12 -receptor antagonism, ticagrelor prevents cell uptake of adenosine and has proven able to augment adenosine effects. Adenosine protects the heart against ischemia-reperfusion injury. We compared the effects of clopidogrel and ticagrelor on myocardial infarct size (IS). Approach and Results-Rats received oral ticagrelor (0, 75, 150, or 300 mg/kg/d) or clopidogrel (30 or 90 mg/kg/d) for 7 days and underwent 30-minute coronary artery ligation and 24-hour reperfusion. Area at risk was assessed by blue dye and IS by 2,3,5-triphenyl-tetrazolium-chloride. Cyclooxygenase-2 (COX2) enzyme activity was assessed by ELISA and expression by real-time polymerase chain reaction. Mechanism responsible was explored using adenosine-receptor antagonist (CGS15943, an A 2A /A 1 antagonist) or cyclooxygenase inhibition by either aspirin (5, 10, or 25 mg/kg) or specific cyclooxygenase-1 (SC560) or COX2 (SC5815) inhibitors. Ticagrelor, dose-dependently, reduced IS, whereas clopidogrel had no effect. Adenosine-receptor antagonism blocked the ticagrelor effect and COX2 inhibition by SC5815, or high-dose aspirin attenuated the IS-limiting effect of ticagrelor, whereas cyclooxygenase-1 inhibition or low-dose aspirin had no effect. Ticagrelor, but not clopidogrel, upregulated COX2 expression and activity. Also this effect was blocked by adenosine-receptor antagonism. Ticagrelor, but not clopidogrel, increased Akt and endothelial nitric oxide synthase phosphorylation. Conclusions-Ticagrelor, but not clopidogrel, reduces myocardial IS. The protective effect of ticagrelor was dependent on adenosine-receptor activation with downstream upregulation of endothelial nitric oxide synthase and COX2 activity. (Arterioscler Thromb Vasc (Y.B.) . The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
T he P2Y 12 -receptor antagonists have shown significant reduction in cardiovascular events in the clinical setting. 1 A combination of aspirin with a P2Y 12 -receptor antagonist is considered to be a cornerstone in the management of patients with acute coronary syndromes (ACS), including ST-elevation myocardial infarction. 2-6 P2Y 12 -receptor antagonists block one of the main amplification pathways of platelet activation (ADP-induced platelet aggregation) and have consistently shown beneficial effects on cardiovascular outcomes in patients with ACS. 1 The PLATelet inhibition and patient Outcomes (PLATO) trial showed that ticagrelor was associated with lower incidence of cardiovascular mortality, myocardial infarction, or stroke compared with clopidogrel in patients with ACS also treated with aspirin. 7, 8 Although the difference was originally ascribed to better and more consistent platelet inhibition, the association of ticagrelor with bradycardia 9 and shortness of breath 10, 11 suggested a role for adenosine. Indeed, ticagrelor has a unique dual mode of action as its P2Y 12 antagonism is complemented by inhibition of adenosine cell uptake, via inhibition of the equilibrative nucleoside transporter-1, thereby increasing extracellular adenosine levels. [12] [13] [14] [15] Adenosine is a major mediator of myocardial protection against ischemia-reperfusion injury and is essential for the myocardial protection by ischemic preconditioning and various pharmacological preconditioning. 16, 17 Statins activate ecto-5′ nucleotidase that convert adenosine monophosphate into adenosine 18 , and the infarct size (IS)-limiting effects of statins are dependent on adenosine-receptor activation. 16, 17, 19 The protective effects of statins are also dependent on downstream cyclooxygenase-2 (COX2) activation, [20] [21] [22] as specific COX2 inhibitors and high-dose aspirin dose-dependently abrogate the IS-limiting effects of statins. 21, 23 The recently reported potential interaction between high maintenance doses of aspirin and ticagrelor 24, 25 could suggest that part of the beneficial effects of ticagrelor are related to COX2 activation and that higher doses of aspirin may attenuate COX2 activity 1 and thereby part of the beneficial effects mediated by ticagrelor.
In this study, we evaluated whether pretreatment with ticagrelor or clopidogrel limits myocardial IS, using an experimental model of transient mechanical coronary artery occlusion that is independent of intraluminal thrombus formation. Next, we studied the signaling pathways mediating this protective effect with special emphasis on the role of adenosine-receptor activation and COX2 activity.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Ticagrelor Limits Myocardial IS
A total of 8 rats died during surgery (2 in the control, 1 in the ticagrelor 75 mg/kg/d, 1 in the ticagrelor 150 mg/kg/d, 2 in the clopidogrel 30 mg/kg/d, and 2 in the clopidogrel 90 mg/kg/d group). Body weight, left ventricular (LV) weight, and the size of the area at risk (AR) were comparable among groups (Table 1) . IS, expressed as percentage of the LV ( Table 1) or percentage of the AR ( Figure 1A) , was significantly and dose-dependently reduced in the ticagrelor-treated animals, whereas clopidogrel at 30 and 90 mg/kg/d had no effect. Hemodynamic data are presented in Figure IA and IB in the online-only Data Supplement.
Plasma levels of ticagrelor 16 hours after the last dose, corresponding to time for coronary artery ligation in the IS experiments, are presented in Figure 1B . Levels were 3.35±0.14, 3.68±0.02, and 6.69±0.07 μM in the ticagrelor 75, 150, and 300 mg/kg/d, respectively.
Both ticagrelor and clopidogrel dose-dependently inhibited platelet aggregation ( Figure 1C ). The differences in level of inhibition between the clopidogrel 30 mg/kg/d and ticagrelor at 75 and 150 mg/kg/d were not significant. Likewise, the difference in inhibition level between clopidogrel 90 mg/ kg/d and ticagrelor 300 or 150 mg/kg/d was not significant, suggesting that both drugs were equally effective in inhibiting platelet aggregation at the doses evaluated with next to complete inhibition achieved at clopidogrel 90 mg/kg/d and ticagrelor 150 mg/kg/d.
Ticagrelor Increases Myocardial COX2 Activity and 6-Keto-PGF1α and 15-Epi-Lipoxin A 4 Levels
COX2 activity was undetectable in the myocardium of the control group. Ticagrelor dose-dependently increased COX2 activity, whereas clopidogrel had no effect ( Figure 1D ). Ticagrelor and clopidogrel did not affect cyclooxygenase-1 activity (data not shown).
Ticagrelor dose-dependently increased both myocardial levels of 6-keto-PGF1α, the stable metabolite of prostacyclin, and 15-epi-lipoxin A 4 , an anti-inflammatory eicosanoid produced by COX2, whereas clopidogrel had no effect ( Figure 1E and 1F).
Cardioprotective Effect of Ticagrelor Is Dependent on Adenosine-Receptor Activation
A total of 5 animals died during surgery (1 in the control, 3 in the CGS15943, and 1 in the ticagrelor+CGS15943 group). Body weight, LV weight, and the size of the AR were comparable among groups (Table 2) . Again, IS, expressed as percentage of the LV ( Table 2 ) or percentage of the AR (Figure 2A ), was significantly reduced by ticagrelor 300 mg/ kg/d relative vehicle-treated animals, whereas clopidogrel 90 mg/kg/d was ineffective. CGS15943 alone (10 mg/kg) or in combination with clopidogrel had no effect on IS, whereas it completely abrogated the IS-limiting effects of ticagrelor (P=0.074 ticagrelor+CGS15943 versus control; P=1.00 versus CGS15943 alone; P=0.001 versus ticagrelor alone). Hemodynamic data are presented in Figure IC and ID in the online-only Data Supplement.
Cardioprotective Effect of Ticagrelor Is Partly Inhibited by High-Dose But Not Low-Dose Aspirin
Two animals died during surgery (1 in the ticagrelor+aspirin 10 mg/kg/d and 1 in the ticagrelor+aspirin 25 mg/kg/d group). Body weight, LV weight, and the size of the AR were comparable among groups ( as percentage of the LV ( Table 3 ) or percentage of the AR ( Figure 2B ), was significantly reduced by ticagrelor 300 mg/kg/d relative to vehicle-treated animals. Aspirin, 5 mg/ kg, did not alter the IS reduction by ticagrelor, but 10 mg/ kg aspirin tended to attenuate and 25 mg/kg partly but significantly (P<0.001) attenuated the IS reduction by ticagrelor ( Figure 2B ).
Cardioprotective Effect of Ticagrelor Is COX2 Dependent
Two animals died during surgery (1 in the control and 1 in the ticagrelor+SC5815 group). Again, body weight, LV weight, and the size of the AR were comparable among groups (Table 4 ). SC5815 and SC560 alone had no effect on IS ( Figure 2C ). As in the previous experiments, IS, expressed as percentage of the LV Figure 1 . A, Infarct size (% of the ischemic area at risk). Number of animals in each group are as in Table 1 . There were significant differences among groups (P<0.001). *P<0.002 vs control; †P<0.001 vs ticagrelor (TIC) 300 mg/ kg/d. B, Ticagrelor blood levels 16 hours after the last dose (n=5 in each group). There were significant differences among groups (P<0.001). *P<0.001 vs control; †P<0.001 vs ticagrelor 300 mg/kg/d. C, Platelet aggregation, induced by 15 μmol/L ADP in platelet reach plasma. There were 5 animals in the control group and 6 in all other groups. There were significant differences among groups (P<0.001). *P<0.002 vs control; †P<0.004 vs ticagrelor 300 mg/kg/d. D, Myocardial cyclooxygenase-2 activity (n=6/group). Overall, there were significant differences among groups (P<0.001). *P<0.004 vs control; †P<0.001 vs ticagrelor 300 mg/kg/d. E, Myocardial 6-keto-PGF1 α levels (n=6/group). Overall, there were significant differences among groups (P<0.001). *P<0.001 vs control; †P<0.03 vs ticagrelor 300 mg/kg/d. F, Myocardial 15-epi-lipoxin A 4 levels (n=6/group). Overall, there were significant differences among groups (P<0.001). *P<0.01 vs control; †P<0.002 vs ticagrelor 300 mg/kg/d. CLOP indicates clopidogrel; and COX2, cyclooxygenase-2. ( Table 4 ) or percentage of the AR ( Figure 2C ), was significantly reduced by ticagrelor 300 mg/kg/d relative to the vehicle-treated animals. The COX2 inhibitor (SC5815) completely abrogated the IS-limiting effect of ticagrelor, whereas the cyclooxygenase-1 inhibitor (SC560) did not interfere with the ticagrelor effect, as IS was comparable between the ticagrelor alone and the ticagrelor+SC560 groups (P=0.939).
Myocardial Adenosine Levels
Ticagrelor 300 mg/kg increased myocardial adenosine levels ( Figure 3A ). Aspirin (25 mg/kg) and CGS15943 (10 mg/kg) alone had no effect on myocardial adenosine levels and they did not alter the ticagrelor effect.
Myocardial Calcium-Dependent and Calcium-Independent Nitric Oxide Synthase Activity
Ticagrelor increased myocardial calcium-dependent nitric oxide synthase (cNOS) activity. Aspirin alone had no effect on cNOS activity and did not block the effect of ticagrelor. On the contrary, CGS15943 completely blocked ticagrelorinduced increase in cNOS activity without affecting cNOS activity when administered alone ( Figure 3B ). In contrast, none of the drugs affected calcium-independent nitric oxide synthase activity (data not shown).
Myocardial Cytosolic Phospholipase A 2 and COX2 Activity
Ticagrelor increased cytosolic phospholipase A 2 (cPLA 2 ; Figure 3C ). Aspirin and CGS15943, administered alone, had no effect on cPLA 2 activity. However, both aspirin and CGS15943 blocked ticagrelor-induced upregulation of cPLA 2 activity. COX2 activity was undetectable in the control group ( Figure 3D) and was significantly increased by ticagrelor. Aspirin and CGS15943, administered alone, had no effect on COX2 activity; but both blocked the augmentation by ticagrelor.
Immunoblotting and Real-Time Polymerase Chain Reaction
Ticagrelor increased P-Akt and phosphorylated endothelial nitric oxide synthase (P-eNOS) levels, without affecting total levels of Akt or eNOS levels ( Figure 4A-4C ). Aspirin alone had no effect on P-Akt or P-eNOS levels and did not block the upregulation by ticagrelor. CGS15943 alone had no effect on P-Akt and P-eNOS levels; however, it completely reversed the increase induced by ticagrelor. Ticagrelor increased COX2 mRNA levels ( Figure 4D ). Aspirin alone had no effect on COX2 mRNA levels, and it did not block the ticagrelor effect. CGS15943 alone had no effect on COX2 mRNA levels, but, it completely abrogated the ticagrelor effect. Table 2 . Overall, there were significant differences among groups (P<0.001). *P<0.001 vs control; †P<0.004 vs ticagrelor (TIC) 300 mg/kg/d. B, Myocardial IS (% of the ischemic AR). Number of animals in each group are as in Table 3 . Overall, there were significant differences among groups (P<0.001). *P<0.001 vs control; †P<0.001 vs ticagrelor 300 mg/kg/d. C, Myocardial IS (% of the ischemic AR; n=4/group). Overall, there were significant differences among groups (P<0.001). *P<0.001 vs control. CGS indicates CGS15943; and CLOP, clopidogrel.
Discussion
The main findings of the present study are that ticagrelor protects against ischemia-reperfusion injury and limits IS. In contrast, despite dosed to similar and next to complete P2Y 12 inhibition as ticagrelor, clopidogrel had no effect on IS. The IS reduction by ticagrelor was highly reproducible as similar reduction was seen in 4 separate experiments. The ticagrelor protective effect was dependent on adenosine-receptor activation with downstream upregulation of eNOS, cPLA 2 , and COX2 enzyme activity. Blocking COX2 with either specific COX2 inhibitor or high-dose aspirin abrogated the IS-limiting effects of ticagrelor. The doses selected for ticagrelor and clopidogrel equally and next to completely inhibited ADP-induced platelet aggregation ( Figure 1C ), confirming that both drugs were compared at equal P2Y 12 inhibition level. Plasma levels of ticagrelor 16 hours after the last dose, at time of coronary ligation, were 3.35±0.14, 3.68±0.02, and 6.69 ± 0.07 μM in the ticagrelor 75, 150, and 300 mg/kg/d, respectively. These values are slightly higher than the C min and C max levels reported in patients following 4 weeks of treatment with the standard dose of 90 mg twice daily (0.4 μM with a SD of 0.2 and 1.4 μM with a SD of 0.7 μM, respectively). 26 Data generated show that ticagrelor, but not clopidogrel, increased myocardial adenosine levels (Figure 3 ). This is in line with prior data that have shown that ticagrelorbut not clopidogrel-treated patients with ACS have elevated plasma adenosine levels. 13 The mechanism responsible for ticagrelor adenosine-related effects has recently been validated to be inhibition of the equilibrative nucleoside transporter-1. 12 The same study also showed that the equilibrative nucleoside transporter-1 inhibition is unique to ticagrelor and not shared with the other P2Y 12 antagonists. 12 Aspirin did not alter the ticagrelor-induced effects on adenosine levels, suggesting that COX2 upregulation is downstream to adenosine-receptor activation. Adenosine is essential for the myocardial protection by ischemic preconditioning and various pharmacological preconditioning. 16, 17 For instance, statins activate ecto-5′ nucleotidase that converts AMP into adenosine 18 , and the IS-limiting effect of statins is dependent on adenosine-receptor activation. 18, 27, 28 We found that the IS-limiting effect of ticagrelor was abrogated with CGS15943, an adenosine-receptor antagonist, whereas CGS15943 alone or in combination with clopidogrel had no effect ( Figure 2 ). Moreover, CGS15943 abolished ticagrelorinduced upregulation of cNOS, cPLA 2 , and COX2 activities (Figure 3 ), upregulation of Akt and eNOS phosphorylation, and upregulation of COX2 mRNA levels (Figure 4) . These data confirm that adenosine-receptor activation mediates the upregulation of the prosurvival pathway by ticagrelor. Both the delayed form of ischemic preconditioning 29 and statins-induced protection 22 are dependent on eNOS activation. We show that ticagrelor, but not clopidogrel, increased cNOS activity ( Figure 3 ) and eNOS phosphorylation at Ser-1177 ( Figure 4) via an adenosine-receptor-dependent mechanism. It has previously been reported that adenosine-receptor activation leads to eNOS phosphorylation 30 and that eNOS activation is essential for downstream upregulation of COX2 activity. 22 The PLATO trial showed that ticagrelor was associated with lower incidence of the composite end point of cardiovascular mortality, myocardial infarction, and stroke than clopidogrel in patients with ACS treated with aspirin. 7, 8 However, a subanalysis of the trial data identified a geographic region interaction (P=0.045), suggesting reduced efficacy of ticagrelor versus clopidogrel in North American patients. 24, 25 Even if play of chance cannot be excluded, an interaction with the maintenance dose of aspirin has been suggested, as higher maintenance doses of aspirin (>300 mg) were used to a greater extent in North America. 25 Retrospective analyses have shown that in patients taking lowmaintenance dose of aspirin, ticagrelor was more effective than clopidogrel in decreasing cardiovascular events regardless of the geographic region. A plausible mechanism was proposed for the interaction between higher aspirin dose and ticagrelor that is linked to the level of P2Y 12 inhibition and the potential prothrombotic effects of high-dose aspirin through the suppression of prostacyclin. 24, 25, 31, 32 However, even though the study design is different, the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis In Myocardial Infarction (TRITON-TIMI) 38 study that compared the effects of prasugrel with clopidogrel showed that prasugrel reduced the risk of the composite of cardiovascular mortality, myocardial infarction, and stroke in patients with ACS scheduled for percutaneous coronary intervention, 33 irrespective of the aspirin dose. 34 Moreover, such an adverse interaction has not been reported to occur between aspirin and clopidogrel in the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. 35 Here, we offer an alternative explanation. In addition to its antiplatelet effect, ticagrelor via its additional mode of action on equilibrative nucleoside transporter-1, an effect not shared by the thienopyridines, provides protection against ischemia-reperfusion injury.
Upregulation of COX2, induced by adenosine, is essential for mediating the myocardial IS-limiting effects of delayed ischemic preconditioning. 29 This has also been shown for statins and pioglitazone. 21, 23, 36 Here, we show that ticagrelor, but not clopidogrel, upregulates COX2 mRNA levels and COX2 activity, resulting in increased levels of prostacyclin, as well as 15-epi-lipoxin A 4. As the protective effect involves COX2 activation with an increased production of prostaglandins, COX2 inhibition by direct COX2 inhibitors or high doses of aspirin abrogates the IS-limiting effect of ticagrelor. Thus, COX2 inhibition by high-dose aspirin and its impact on the IS-limiting effect of ticagrelor (and potential other eicosanoid-mediated effects) may explain the association between high maintenance dose of aspirin and decrease in relative efficacy of ticagrelor. A recent study has also found that ticagrelor, but not clopidogrel, induced COX2 expression in vitro in primary human aortic endothelial cells stimulated with tumor necrosis factor-α. 37 In addition to upregulation of COX2, ticagrelor increased cPLA 2 activity (Figure 3 ). This effect was blocked by the adenosine-receptor inhibitor (CGS15943) and aspirin. We have previously shown that atorvastatin increases myocardial cPLA 2 expression and activity in the rat. 21, 36 Valdecoxib (a specific COX2 inhibitor) 21 attenuates the effects of statins. Aspirin 38, 39 and sulindac (a nonspecific cyclooxygenase inhibitor) decreases cPLA 2 mRNA expression. 39 As cPLA 2 is the major enzyme that supplies arachidonic acid to the COX2 for the production of protective prostaglandins, augmentation of cPLA 2 activity may contributes to the protective effect of ticagrelor. Indeed, cPLA 2 is involved in protecting the heart against ischemia-reperfusion injury. 40 Thus, both statins and ticagrelor share a similar adenosinedependent mode of action, as statins can increase the production of adenosine (by activating ecto-5′ nucleotidase) and ticagrelor conserves its extracelular presence by protecting it from its intracelular metabolism. Both mechanism leads to increased adenosine levels providing local enhanced adenosine-receptor activation with downstream activation of Akt, eNOS, and COX2. Similar synergistic effects on IS limitation was described using atorvastatin and dipyridamole (an adenosine reuptake inhibitor). 41 The IS-limiting effect of both statins and ticagrelor is abrogated by COX2 inhibition with either a specific inhibitor or high-dose aspirin. Thus, an additive, if not synergistic effects, can be hypothesized for ticagrelor and statins. Indeed, the superiority of ticagrelor over clopidogrel in the PLATO trial seems to be reduced in patients not taking lipid-lowering drugs at randomization (P=0.04 for the interaction). 7 Clearly, such an observation is limited, as no information exists about the continued intake of statins. But, if one assume the majority of patients that are on statins at randomization continues throughout the study, the data are hypothesis generating.
Wang et al 42 compared the effect of intravenous ticagrelor and clopidogrel, added to intravenous thrombolytic therapy with tissue plasminogen activator in dogs with electrolytic injuryinduced intracoronary thrombus. 42 In this model, ticagrelor, but not clopidogrel, reduced myocardial IS by ≈60%. As both clopidogrel and ticagrelor, like in our study, were dosed to complete inhibition of ex vivo ADP-induced aggregation, they also raised the possibility that the beneficial effect could be mediated by nonplatelet mechanisms, including inhibition of vascular P2Y 12 or via adenosine uptake inhibition. 42 Yang et al, 43 on the other hand, found that 2-day pretreatment with clopidogrel (15 mg/kg) significantly reduce myocardial IS in rabbits exposed to 30-minute ischemia and 3-hour reperfusion. The protective effect of clopidogrel was abrogated with MRS1754, a selective adenosine A 2B receptor blocker, and wortmannin, a PI3 kinase/Akt inhibitor. Intravenous infusion of the short-acting P2Y 12 antagonist cangrelor (60 μg/kg bolus 10 minutes before reperfusion followed by 6 μg/kg/min for 3 hours) also reduced IS in their model. 43 The explanation for the difference between the studies concerning the protective effects of clopidogrel is unclear and might be related to the species, the dose, the length of reperfusion (3 versus 24 hour), or a random effect. Importantly, in our study as in the study by Wang et al 42 , ticagrelor and clopidogrel were compared at doses providing equally platelet inhibition level. Therefore, the lack of IS-limiting effect of clopidogrel cannot be explained by suboptimal P2Y 12 inhibition.
We have tested the effects of 7-day preconditioning with ticagrelor or clopidogrel on myocardial protection; thus, it may be considered to represent a form of "delayed preconditioning." Currently, we are studying the effects of treatment administered just before reperfusion. This issue should be addressed in further studies. Currently, ticagrelor is indicated for patients after ACSs. The PLATO trial included patients with ST-elevation myocardial infarction and patients with non-ST-elevation ACSs. The duration of therapy in PLATO was 6 to 12 months (median, 277 days) post ACS, and follow-up for outcomes was 1 year. 8 Thus, the PLATO study assesses the outcomes of long-term and not just the acute administration before reperfusion. Most of the clinical events occur 60 days and more after study initiation. Hence, our study imitates a clinical scenario of a patient who develops acute ischemia while being treated with ticagrelor versus clopidogrel for an intermediate or long-term duration.
Conclusions
In addition to its potent P2Y 12 antagonism, ticagrelor increases adenosine levels resulting in adenosine-receptor-mediated activation of Akt, eNOS, and COX2. This in turn results in increased production of prostacyclin and 15-epi-lipoxin A 4 and a reduction in IS following ischemia-reperfusion. The protective effect is reversed by adenosine-receptor antagonism but also abrogated with high-dose aspirin, as well as selective COX2 inhibition. This may help explain the mortality benefit seen with ticagrelor and the clinical paradox observed showing reduced efficacy of ticagrelor at higher maintenance doses of aspirin. Further studies are needed to determine the importance of the myocardial protective effects of ticagrelor in the clinical setting.
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